Sexual health in long-term breast cancer survivors.

Abstract:

PURPOSE:Sexual dysfunction is reported in women with breast cancer (BC). It is unclear whether symptoms persist over time as data comparing long-term survivors to controls are lacking. We compared sexual functioning in long-term breast cancer survivors (BCS) to controls and determined the impact of adjuvant therapy on sexual health. METHODS:A cohort of women with localized BC (1989-1996) was prospectively followed. BCS and controls (2005-2007) completed self-reported questionnaires. Sexual health was measured with the Sexual Activity Questionnaire (SAQ). Vasomotor, gynecological, and bladder symptoms were scored using the Menopausal Symptom Scale. Regression analysis was used to compare groups, with adjustment for age and secondly menopausal status. RESULTS:BCS (n = 248, 87%) and controls (n = 159, 95%) completed the SAQ at a median time from diagnosis of 12.5 years. BCS were older (62 vs 59 years, p = 0.0004) and more likely to be menopausal (94 vs 86%, p = 0.0025). Sexual activity did not differ significantly between BCS and controls, but when adjusted for menopausal status, pre/peri-menopausal BCS were less likely to be sexually active than pre/peri-controls (odds ratio OR 0.12, p = 0.012). In those sexually active, no significant differences were noted on the SAQ Pleasure, Discomfort, and Habit scales. BCS reported worse gynecological symptoms and pre/peri-menopausal patients had more bladder complaints (standardized effect size 0.36 p = 0.002 and 1.11, p = 0.011). Adjuvant treatments were not significantly associated with sexual function, but BCS treated with chemotherapy reported worse gynecological symptoms. CONCLUSION:Sexual health and uro-genital symptom counseling should be provided to BCS, particularly pre/peri-menopausal patients, even at long-term follow-up.

authors

Soldera SV,Ennis M,Lohmann AE,Goodwin PJ

doi

10.1007/s10549-018-4894-8

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

159-166

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-4894-8

journal_volume

172

pub_type

杂志文章
  • Cytogenetic evaluation of 20 sporadic breast cancer patients and their first degree relatives.

    abstract::Many genetic abnormalities disclosed even in somatic cells like peripheral blood lymphocytes may mark footprint(s) of malignancy(ies). The present cytogenetic study on peripheral blood lymphocytes of sporadic breast cancer patients (n = 20) and their first degree relatives (n = 39) reports abnormalities of chromosomes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005951125574

    authors: Trivedi AH,Roy SK,Bhachech SH,Patel RK,Dalal AA,Bhatavdekar JM,Patel DD

    更新日期:1998-03-01 00:00:00

  • Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

    abstract::Cytoplasmic HuR is associated with reduced survival in invasive breast cancer. We designed this study to determine the predictive and prognostic value of HuR expression in women with breast cancer who underwent neoadjuvant chemotherapy followed by surgical resection. We immunohistochemically analyzed cytoplasmic HuR e...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-013-2679-7

    authors: Wang J,Li D,Wang B,Wu Y

    更新日期:2013-09-01 00:00:00

  • YouTube English videos as a source of information on breast self-examination.

    abstract:OBJECTIVE:To examine the content, quality and reliability of YouTube videos related to breast self-examination. DESIGN:A search of YouTube was made on 21.06.2018 using the keyword of "breast self-examination". The videos were categorised by two doctors as useful information or misleading information. To evaluate the q...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-018-5044-z

    authors: Esen E,Aslan M,Sonbahar BÇ,Kerimoğlu RS

    更新日期:2019-02-01 00:00:00

  • Characterization of chemotherapy-induced peripheral neuropathy using patient-reported outcomes and quantitative sensory testing.

    abstract:PURPOSE:Chemotherapy-induced peripheral neuropathy (CIPN) is a common, debilitating side effect in cancer survivors. This study aimed to assess the characteristics of quantitative sensory testing (QST) and its correlation with patient-reported outcomes (PROs) in cancer patients with and without CIPN. METHODS:We conduc...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-020-06079-2

    authors: Zhi WI,Baser RE,Kwon A,Chen C,Li SQ,Piulson L,Seluzicki C,Panageas KS,Harte SE,Mao JJ,Bao T

    更新日期:2021-01-28 00:00:00

  • Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

    abstract::The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials. Two pharmacological studies are reported which assess the use of one of these inh...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1006289811540

    authors: Dowsett M,Doody D,Miall S,Howes A,English J,Coombes RC

    更新日期:1999-07-01 00:00:00

  • The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT.

    abstract:PURPOSE:In rodents, a single exercise bout performed 24 h prior to a single doxorubicin treatment provides cardio-protection. This study investigated whether performing this intervention prior to every doxorubicin treatment for breast cancer reduced subclinical cardiotoxicity and treatment symptoms. METHODS:Twenty-fou...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-017-4554-4

    authors: Kirkham AA,Eves ND,Shave RE,Bland KA,Bovard J,Gelmon KA,Virani SA,McKenzie DC,Stöhr EJ,Waburton DER,Campbell KL

    更新日期:2018-02-01 00:00:00

  • Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

    abstract::This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evalu...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章

    doi:10.1023/a:1006320122711

    authors: Goss PE,Oza A,Goel R,Nabholtz JM,De Coster R,Bruynseels J,Reid C,Wadden N,Crump M,Tye LM

    更新日期:2000-01-01 00:00:00

  • T-Type voltage gated calcium channels: a target in breast cancer?

    abstract:PURPOSE:The purpose of this review article is to discuss the potential of T-type voltage gated calcium channels (VGCCs) as drug targets in breast cancer. Breast cancer, attributable to the different molecular subtypes, has a crucial need for therapeutic strategies to counter the mortality rate. VGCCs play an important ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-018-4970-0

    authors: Bhargava A,Saha S

    更新日期:2019-01-01 00:00:00

  • Validation of an oligo-gene signature for the prognostic stratification of ductal carcinoma in situ (DCIS).

    abstract::Current evidence suggests that the majority of DCIS lesions do not progress to invasive carcinoma, and overtreatment of DCIS is a significant problem. We previously reported an 8-gene signature that differentiated microdissected low-grade (LG) DCIS lesions with and without associated stromal invasion, based on differe...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-3838-4

    authors: Geradts J,Groth J,Wu Y,Jin G

    更新日期:2016-06-01 00:00:00

  • Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

    abstract:PURPOSE:We conducted an exploratory biomarker study from a phase II clinical trial of eribulin plus gemcitabine (EG) versus paclitaxel plus gemcitabine (PG) in HER2-negative metastatic breast cancer (BC) patients. METHODS:We performed targeted deep sequencing with a customized cancer gene panel and RNA expression assa...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-019-05400-y

    authors: Kim JY,Lee E,Park K,Im SA,Sohn J,Lee KS,Chae YS,Kim JH,Kim TY,Jung KH,Park YH,Breast Cancer Committee of the Korean Cancer Study Group.

    更新日期:2019-11-01 00:00:00

  • Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease.

    abstract::The third category for extent of involution in Table 4 was published incorrectly in the original publication. The correct classification is ≥ 75% and the corrected Table 4 is given in the Correction article. ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s10549-018-4780-4

    authors: Arthur R,Wang Y,Ye K,Glass AG,Ginsberg M,Loudig O,Rohan T

    更新日期:2018-07-01 00:00:00

  • Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.

    abstract:PURPOSE:The independent predictive information from progesterone receptor (PgR) positivity for breast cancer treated with tamoxifen has been questioned after an overview by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). However, the studies in the overview were to a large content performed before mode...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-016-4007-5

    authors: Nordenskjöld A,Fohlin H,Fornander T,Löfdahl B,Skoog L,Stål O

    更新日期:2016-11-01 00:00:00

  • FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.

    abstract:PURPOSE:Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer and associated with early metastasis, drug resistance, and poor patient survival. Fork head box M1 (FOXM1) is considered as an emerging molecular target due to its oncogenic role and high overexpression profile in 85% in TNBC. However, ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4207-7

    authors: Hamurcu Z,Kahraman N,Ashour A,Ozpolat B

    更新日期:2017-06-01 00:00:00

  • Psychosocial and physical outcomes of primary breast cancer therapy: mastectomy vs excisional biopsy and irradiation.

    abstract::Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside fro...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF01807591

    authors: Schain W,Edwards BK,Gorrell CR,de Moss EV,Lippman ME,Gerber LH,Lichter AS

    更新日期:1983-01-01 00:00:00

  • Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

    abstract::Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3556-3

    authors: Debald M,Abramian A,Nemes L,Döbler M,Kaiser C,Keyver-Paik MD,Leutner C,Höller T,Braun M,Kuhl C,Kuhn W,Schild HH

    更新日期:2015-10-01 00:00:00

  • Indium-111-octreotide scintigraphy, intraoperative gamma-detector localisation and somatostatin receptor expression in primary human breast cancer.

    abstract::12 women with primary breast cancer underwent somatostatin receptor scintigraphy (SRS) with 111In-DTPA-D-Phe1-octreotide. The tumour sizes varied between 2 and 5 cm and were all, except one, palpable at clinical examination. Tumour biopsies were taken with additional sampling from normal breast tissue, fat, muscle, ax...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1016120529858

    authors: Skånberg J,Ahlman H,Benjegård SA,Fjälling M,Forssell-Aronsson EB,Hashemi SH,Nilsson O,Suurkula M,Jansson S

    更新日期:2002-07-01 00:00:00

  • Disease-free probability after the first primary ductal carcinoma in situ of the breast: a comparison between African-American and White-American women.

    abstract::Compelling evidence about the differences in the biology and behavior of invasive breast cancer between African-American (AA) and White-American (WA) women motivate inquiry into comparing the clinicopathology of non-invasive breast cancer (ductal carcinoma in situ, DCIS). AA and WA women diagnosed with their first pri...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-011-1742-5

    authors: Stark A,Stapp R,Raghunathan A,Yan X,Kirchner HL,Griggs J,Newman L,Chitale D,Dick A

    更新日期:2012-01-01 00:00:00

  • Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features.

    abstract::Mucinous breast cancer (MBC) is mainly a disease of postmenopausal women. Pure MBC is rare and augurs a good prognosis. In contrast, MBC mixed with other histological subtypes of invasive disease loses the more favorable prognosis. Because of the relative rarity of pure MBC, little is known about its cell and tumor bi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-012-2377-x

    authors: Jambal P,Badtke MM,Harrell JC,Borges VF,Post MD,Sollender GE,Spillman MA,Horwitz KB,Jacobsen BM

    更新日期:2013-01-01 00:00:00

  • Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment.

    abstract::The concept of cancer cells being hierarchically organized and arising from their own progenitor stem cells will have important implications on cancer therapy. If this hypothesis were to be true then the paucity of estrogen receptors in stem cells as well as their inherent drug resistance mechanisms pose a challenge t...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-009-0619-3

    authors: Resetkova E,Reis-Filho JS,Jain RK,Mehta R,Thorat MA,Nakshatri H,Badve S

    更新日期:2010-08-01 00:00:00

  • Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy.

    abstract::Neurotoxicity is a common side-effect during taxane therapy. The prevalence and severity of long-term neurotoxicity following therapy is unknown. The authors conducted a cross-sectional study of 50 consecutive patients with stage I-III BC, who were within 6 months and 2 years of completing adjuvant taxane therapy and ...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1278-0

    authors: Hershman DL,Weimer LH,Wang A,Kranwinkel G,Brafman L,Fuentes D,Awad D,Crew KD

    更新日期:2011-02-01 00:00:00

  • Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ.

    abstract::Currently, there are no applied molecular markers to aid in predicting risk of carcinoma in situ (CIS) progression to invasive cancer, and therefore, all women diagnosed with CIS undergo surgery. Standard assessment of protein expression in fixed tissue by immunohistochemistry (IHC) is not quantitative and hence is no...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-1227-y

    authors: Furstenau DK,Mitra N,Wan F,Lewis R,Feldman MD,Fraker DL,Guvakova MA

    更新日期:2011-09-01 00:00:00

  • Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen.

    abstract::The purpose of this study is to compare immunohistochemistry (IHC) and cytosol-based assays for determination of estrogen receptor (ER) and prediction of response to adjuvant tamoxifen treatment in postmenopausal women with early-stage invasive breast cancer. The Stockholm Breast Cancer Study Group conducted a randomi...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s10549-010-1202-7

    authors: Khoshnoud MR,Löfdahl B,Fohlin H,Fornander T,Stål O,Skoog L,Bergh J,Nordenskjöld B

    更新日期:2011-04-01 00:00:00

  • Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells.

    abstract::The present study was undertaken to compare ROH growth responsiveness between normal human mammary epithelial cells (HMECs), estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cells, and assess whether this responsiveness is correlated with differences in ROH metabolism, particularly RA synthes...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1014815112078

    authors: Hayden LJ,Satre MA

    更新日期:2002-03-01 00:00:00

  • Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women.

    abstract::Tamoxifen citrate is a synthetic antiestrogen that provides survival benefit when given as adjuvant treatment in postmenopausal women with breast cancer. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible procoagulant effects assoc...

    journal_title:Breast cancer research and treatment

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1007/BF00665973

    authors: Mamby CC,Love RR,Feyzi JM

    更新日期:1994-01-01 00:00:00

  • Gene-based analysis of the fibroblast growth factor receptor signaling pathway in relation to breast cancer in African American women: the AMBER consortium.

    abstract::We conducted gene-based analysis in 26 genes in the FGFR signaling pathway to identify genes carrying genetic variation affecting risk of breast cancer and the specific estrogen receptor (ER) subtypes. Tagging single-nucleotide polymorphisms (SNPs) for each gene were selected and genotyped on a customized Illumina Exo...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-015-3672-0

    authors: Ruiz-Narváez EA,Haddad SA,Lunetta KL,Yao S,Bensen JT,Sucheston-Campbell LE,Hong CC,Haiman CA,Olshan AF,Ambrosone CB,Palmer JR

    更新日期:2016-01-01 00:00:00

  • National consensus recommendations on patient-centered care for ductal carcinoma in situ.

    abstract:PURPOSE:The purpose of this research was to generate recommendations on strategies to achieve patient-centered care (PCC) for ductal carcinoma in situ (DCIS). METHODS:Thirty clinicians (surgeons, medical/radiation oncologists, radiologists, nurses, navigators) who manage DCIS and 32 DCIS survivors aged 18 or older wer...

    journal_title:Breast cancer research and treatment

    pub_type: 共识发展会议,杂志文章,评审

    doi:10.1007/s10549-019-05132-z

    authors: Gagliardi AR,Wright FC,Look Hong NJ,Groot G,Helyer L,Meiers P,Quan ML,Urquhart R,Warburton R

    更新日期:2019-04-01 00:00:00

  • A scoping review characterizing "Choosing Wisely®" recommendations for breast cancer management.

    abstract:PURPOSE:Choosing Wisely (CW)® was created by the American Board of Internal Medicine (ABIM) to promote patient-physician conversations about unnecessary medical interventions. Similarly, other countries created their own panels of experts called "CW® campaigns" which review recommendations submitted by that country's o...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章,评审

    doi:10.1007/s10549-020-06009-2

    authors: Shah H,Surujballi J,Awan AA,Hutton B,Arnaout A,Shorr R,Vandermeer L,Alzahrani MJ,Clemons M

    更新日期:2020-11-06 00:00:00

  • Weight gain in hormone receptor-positive (HR+) early-stage breast cancer: is it menopausal status or something else?

    abstract:PURPOSE:This study investigates weight trajectories in pre- versus postmenopausal breast cancer (BC) survivors diagnosed with hormone receptor-positive tumors, with a specific focus on discerning menopausal status and type of endocrine treatment (ET) as risk factors for weight gain during ET. METHODS:We conducted a re...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-017-4501-4

    authors: Nyrop KA,Deal AM,Lee JT,Muss HB,Choi SK,Wheless A,Carey LA,Shachar SS

    更新日期:2018-01-01 00:00:00

  • ROCK: a breast cancer functional genomics resource.

    abstract::The clinical and pathological heterogeneity of breast cancer has instigated efforts to stratify breast cancer sub-types according to molecular profiles. These profiling efforts are now being augmented by large-scale functional screening of breast tumour cell lines, using approaches such as RNA interference. We have de...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1007/s10549-010-0945-5

    authors: Sims D,Bursteinas B,Gao Q,Jain E,MacKay A,Mitsopoulos C,Zvelebil M

    更新日期:2010-11-01 00:00:00

  • An assessment of the influence of clinical breast examination reports on the interpretation of mammograms in a breast screening program. Ontario Breast Screening Program Radiologists Research Group.

    abstract::The population-based Ontario Breast Screening Program (OBSP) provides two-yearly screening by both nurse examiner clinical breast examination (CBE) and two-view mammography to women aged 50 to 69. CBE alone accounts for about 5% of cancer detection. The purpose of this study was to determine whether CBE information af...

    journal_title:Breast cancer research and treatment

    pub_type: 杂志文章

    doi:10.1023/a:1005990806919

    authors: Knight JA,Libstug AR,Moravan V,Boyd NF

    更新日期:1998-03-01 00:00:00